BR112013009624A2 - uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr - Google Patents

uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr

Info

Publication number
BR112013009624A2
BR112013009624A2 BR112013009624A BR112013009624A BR112013009624A2 BR 112013009624 A2 BR112013009624 A2 BR 112013009624A2 BR 112013009624 A BR112013009624 A BR 112013009624A BR 112013009624 A BR112013009624 A BR 112013009624A BR 112013009624 A2 BR112013009624 A2 BR 112013009624A2
Authority
BR
Brazil
Prior art keywords
diseases
egfr
treatment
acquired resistance
compounds
Prior art date
Application number
BR112013009624A
Other languages
English (en)
Portuguese (pt)
Inventor
Carlos Garcia-Echeverria
Christian René Schnell
Christine Fritsch
Saskia Maria Brachmann
Sauveur-Michel Maira
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013009624A2 publication Critical patent/BR112013009624A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112013009624A 2010-11-08 2011-11-07 uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr BR112013009624A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41111710P 2010-11-08 2010-11-08
PCT/EP2011/069522 WO2012062694A1 (en) 2010-11-08 2011-11-07 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members

Publications (1)

Publication Number Publication Date
BR112013009624A2 true BR112013009624A2 (pt) 2016-07-12

Family

ID=44947083

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009624A BR112013009624A2 (pt) 2010-11-08 2011-11-07 uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr

Country Status (12)

Country Link
US (4) US20130209461A1 (https=)
EP (1) EP2637661B1 (https=)
JP (4) JP2013542228A (https=)
KR (1) KR101854484B1 (https=)
CN (2) CN103200943A (https=)
AU (1) AU2011328227B2 (https=)
BR (1) BR112013009624A2 (https=)
CA (1) CA2815492C (https=)
MX (1) MX360157B (https=)
RU (1) RU2589695C2 (https=)
TR (1) TR201802943T4 (https=)
WO (1) WO2012062694A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014004559A (es) * 2011-10-14 2014-08-01 Novartis Ag Derivados de 2-carboxamida cicloamino urea en combinacion con inhibidores de hsp90 para el tratamiento de enfermedades proliferativas.
CA2853582A1 (en) * 2011-11-02 2013-05-10 Novartis Ag 2-carboxamide cycloamino urea derivatives for use in treating vegf - dependent diseases
TR201904980T4 (tr) * 2012-08-07 2019-05-21 Novartis Ag Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
HK1211476A1 (en) * 2012-08-16 2016-05-27 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
BR112015025101A2 (pt) * 2013-04-05 2017-07-18 Sanofi Sa composição antitumoral que compreende um inibidor pi3kbeta-seletivo e um inibidor pi3kalfa-seletivo
SI3076969T1 (sl) * 2013-12-06 2021-12-31 Novartis Ag Režim omderjanja izooblike alfa selektivnega zaviralca fosfatidilino- zitol 3-kinaze
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
EP2240475B1 (en) * 2007-12-20 2013-09-25 Novartis AG Thiazole derivatives used as pi 3 kinase inhibitors
NZ602675A (en) * 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

Also Published As

Publication number Publication date
JP2016222686A (ja) 2016-12-28
US20200022967A1 (en) 2020-01-23
US20180325883A1 (en) 2018-11-15
US20130209461A1 (en) 2013-08-15
AU2011328227B2 (en) 2015-04-09
MX360157B (es) 2018-10-24
CA2815492C (en) 2019-04-09
JP2019048822A (ja) 2019-03-28
RU2589695C2 (ru) 2016-07-10
RU2013126485A (ru) 2014-12-20
JP2013542228A (ja) 2013-11-21
KR20130143582A (ko) 2013-12-31
CN103200943A (zh) 2013-07-10
CA2815492A1 (en) 2012-05-18
CN105412105A (zh) 2016-03-23
WO2012062694A1 (en) 2012-05-18
MX2013005182A (es) 2013-07-03
EP2637661A1 (en) 2013-09-18
JP2020114849A (ja) 2020-07-30
AU2011328227A1 (en) 2013-04-18
EP2637661B1 (en) 2017-12-20
TR201802943T4 (tr) 2018-03-21
KR101854484B1 (ko) 2018-05-03
US20150250778A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
BR112013009624A2 (pt) uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BRPI0909082A2 (pt) imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BRPI0923231B1 (pt) anticorpo anti-cmet, composição que compreende, e usos do anticorpo e da composição.
CR20110270A (es) Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015008447A2 (pt) métodos para tratar câncer
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
BR112013027119A8 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
BR112014008400A2 (pt) derivados de 2-carboxamida cicloamino ureia em combinação com os inibidores de hsp90 para o tratamento de doenças proliferativas
BR112012010995A2 (pt) revestimentos e métodos de revestimento de agulhas cirúrgicas
BR112014011868A2 (pt) composições corantes poliméricas e métodos de uso
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112015014532A2 (pt) composições cosméticas de fluido de eclosão de peixe

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2643 DE 31-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.